ERBB2 and triple-negative breast carcinoma: Median PFS was 19.5 months (95% CI, 15.4 to 26.9 months), 16.4 months (95% CI, 12 to 21.7 months), 11.4 months (95% CI, 8.2 to 13.8 months), and 7.9 months (95% CI, 5.7 to 12.8 months) for HR, HR plus HER2/neu, HER2/neu, and triple-negative breast cancer (TNBC) patients, respectively (Fig 2).